Company Filing History:
Years Active: 1997-1998
Title: Innovations by Henry Hoppe, Iv in Cystic Fibrosis Treatment
Introduction
Henry Hoppe, Iv is an accomplished inventor based in Acton, MA (US). He has made significant contributions to the field of medical research, particularly in the treatment of cystic fibrosis. With a total of 2 patents, his work focuses on innovative methods and therapeutic compositions aimed at improving the lives of those afflicted with this condition.
Latest Patents
Henry's latest patents include groundbreaking methods for treating cystic fibrosis. One patent describes methods involving the administration of a protein enhancing agent, differentiating agent, and/or carboxy-compound to subjects afflicted with cystic fibrosis. This approach aims to restore functionality to the mutant cystic fibrosis transmembrane regulator protein present within cystic fibrosis-associated cells. Another patent outlines methods and compositions for mobilizing mutant forms of CFTR, which retain some functional activity, to the plasma membrane. This process enables these proteins to mediate chloride ion transport, which is crucial for proper lung function.
Career Highlights
Henry Hoppe, Iv is currently associated with Genzyme Corporation, a leading biotechnology company known for its innovative therapies. His work at Genzyme has allowed him to focus on developing treatments that address the underlying causes of cystic fibrosis, making a significant impact in the field of respiratory health.
Collaborations
Henry has collaborated with notable colleagues such as Seng H Cheng and Shaona Lee Fang. Their combined expertise has contributed to the advancement of research and development in cystic fibrosis therapies.
Conclusion
Henry Hoppe, Iv's innovative work in the treatment of cystic fibrosis showcases his dedication to improving patient outcomes through scientific research. His patents reflect a commitment to finding effective solutions for a challenging medical condition.